Strategic Alliance Between Mycenax and SPERA PHARMA
Mycenax Biotech Inc. (TWO:4726), a premier biologics contract development and manufacturing organization (CDMO), has announced a significant strategic alliance with SPERA PHARMA Inc., a renowned expert in pharmaceutical Chemistry, Manufacturing, and Controls (CMC). This partnership aims to leverage the strengths of both companies to provide a comprehensive solution for antibody-drug conjugates (ADCs) and bioconjugates, with a focus on linker/payload synthesis, drug substance production, formulation, and aseptic fill-finish services.
Accelerating Biopharmaceutical Development
The collaboration intends to enhance the timeline for biopharmaceutical companies by offering an integrated, cost-effective platform for ADC development and manufacturing. Mycenax’s extensive biologics services combined with SPERA PHARMA's expertise in CMC, particularly in high-potency fill-finish services for ADCs, enables the partnership to provide tailored, one-stop solutions for global clients.
SPERA PHARMA’s Expertise
SPERA PHARMA, established in 2017 as a spin-off from Takeda Pharmaceutical Company’s CMC Research Division, has gained recognition for its profound knowledge in complex drug development. Their specialties include process chemistry, formulation, analytical development, and GMP-compliant aseptic manufacturing. With a foundation stemming from Japan's distinguished pharmaceutical heritage, SPERA PHARMA has established its reputation as one of the top CDMOs, earning the trust of global partners through technical excellence and comprehensive CMC solutions.
Mycenax’s Commitment to Quality
Mycenax has been audited by international regulatory agencies, including EMA, PMDA, and Health Canada, confirming its commitment to meeting high-quality standards in biologics manufacturing. Their strategic partnership with Krisan Biotech, formed in 2022, has expanded their ADC technology platform, further enhancing their capabilities in the global marketplace.
Empowering ADC Developers
Through their collaboration, Mycenax and SPERA PHARMA are positioned to deliver an end-to-end development and manufacturing solution that empowers ADC developers worldwide. This partnership facilitates speed, flexibility, and a level of technical excellence that is essential in today’s rapidly evolving biopharmaceutical landscape.
About SPERA PHARMA
Founded in July 2017 in Osaka, Japan, SPERA PHARMA specializes in CMC services, offering comprehensive support across all phases of pharmaceutical development, from early research through to regulatory approval. Their team comprises highly skilled researchers dedicated to providing flexible and effective CMC solutions tailored to the needs of their global client base.
About Mycenax
Mycenax is a Taiwan-based CDMO that provides integrated biologics solutions ranging from process development to cGMP-compliant manufacturing. With two GMP-compliant manufacturing facilities and a commitment to advancing ADC therapeutics, Mycenax continually strives to meet the growing demand for biopharmaceutical products worldwide.
Frequently Asked Questions
What is the goal of the Mycenax and SPERA PHARMA alliance?
The goal is to provide a comprehensive and efficient solution for ADC drug substance and product manufacturing.
What experience does SPERA PHARMA bring to the partnership?
SPERA PHARMA brings expertise in complex drug development, including process chemistry, formulation, and GMP-compliant manufacturing.
How does Mycenax ensure quality in its manufacturing processes?
Mycenax is audited by various international regulatory agencies, ensuring compliance and quality standards in its production.
What additional capabilities does the partnership enhance for ADC developers?
The partnership enhances speed, flexibility, and technical excellence in developing ADC therapeutics.
When was SPERA PHARMA founded?
SPERA PHARMA was founded in July 2017 in Osaka, Japan, as a spin-off from Takeda Pharmaceutical’s CMC Research Division.
